Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PCV13i in Healthy People
NCT04100772Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- May 2020
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of iPneucia in pneumococcal infection (8 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Safety items of adverse reactions at 7 days, Safety items of SAE at 6 months and 5 more. Started May 2020; status: completed.
02
Drugs
iPneucia
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04100772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100772.